[19]
ICH. ICH Q1A (R2) stability testing of new drug substances and drug products - Scientific guideline . 2003. 4(Feburary), 24
[20]
Breaux, J.; Jones, K.; Boulas, P. Analytical methods development and validation. Pharm. Technol., 2003, 1, 6-13.
[33]
Iram, F.; Iram, H.; Iqbal, A.; Husain, A. Forced degradation studies. J. Anal. Pharm. Res., 2016, 3(6), 73.
[34]
Ngwa, G. Forced degradation as an integral part of HPLC stability-indicating method development. Drug Deliv Technol., 2010, 10(5), 56-59.
[38]
Picollo, M.; Aceto, M.; Vitorino, T. UV-Vis spectroscopy. Phys Sci Rev., 2018, 4(4), 20180008.
[41]
O’Haver, T.C.; Fell, A.F.; Smith, G.; Gans, P.; Sneddon, J.; Bezur, L. Derivative spectroscopy and its applications in analysis; Royal Society of Chemistry, 1982, pp. 22-46.
[43]
Sivasankara Rao, G.; Venkat Rao, S.; Vardhan, S.V.M.; Ramachandran, D. Development and validation of new UV-spectrophotometric assay method for valsartan in pure and in formulations. J. Chem. Pharm. Res., 2013, 5(7), 229-232.
[44]
Gupta, K.; Wadodkar, A.; Wadodkar, S. UV-Spectrophotometric methods for estimation of Valsartan in bulk and tablet dosage form. Int. J. Chemtech Res., 2010, 2.
[48]
Surwade, K.; Saudagar, R. UV spectrophotometric method for the estimation of azilsartanmedoxomil in bulk and pharmaceutical formulations. World J. Pharm. Res., 2015, 4(1), 1667-1672.
[56]
Ali, AH High-performance liquid chromatography (HPLC): A review. Ann Adv Chem, 2022, 6, 010-20.
[59]
Ravisankar, P.; Devi, M.S.; Ravali, B.; Tejaswini, K.; Balaji, D.; Babu, P. Rapid simultaneous separation of four sartans by isocratic RP-HPLC method: Application to determination of olmisartan in pharmaceutical dosage form. J Chem Pharm Sci., 2015, 8(1), 61.
[66]
Suhagia, B.N.; Shah, R.R.; Patel, D.M. Development of a RP-HPLC method for evaluating losartan potassium and hydrochlorthiazide tablets. Indian J. Pharm. Sci., 2005, 67, 37-42.
[72]
Kasimala, M.B.; Kasimala, B.B. Reverse phase-HPLC method development and validation for the Simultaneous estimation of azilsartanmedoxomil and Chlortalidone in pharmaceutical dosage forms. J At Mol., 2012, 2(1), 117.
[73]
Sravani, P.; Rubesh Kumar, S.; Duganath, N.; Devanna, N. Method development and validation for the simultaneous estimation of azilsartan and chlorthalidone by RP-HPLC in pharmaceutical dosage form. Int. J. Pharma Sci., 2014, 4(5), 725-729.
[75]
Kumar, T.H.; Begum, A.; Sankar, D.G. Determination of azilsartanmedoximil and chlorthalidone in tablets exposed to forced degradation by using RP-HPLC. Biomed. Res. (Aligarh), 2019, 30(5), 10-35841.
[76]
Nalawade, V.; Joshi, S. Development and validation of LC-MS/MS method for simultaneous determination of azilsartanmedoxomil and chlorthalidone from the human plasma. J Pharm Sci Res., 2019, 11(7), 2533-2537.
[80]
Swartz, M.E. Journal of liquid chromatography & related technologies UPLC: An introduction and review. J Liq Cromatography Relat Technol., 2013, 2005, 37-41.
[88]
Wang, C.C.; Lan, T. Determination and pharmacokinetic study of azilsartan in rat plasma by UPLC-MS/MS. Lat. Am. J. Pharm., 2019, 38(10), 1938-1944.
[91]
Dedhiya, P.P.; Patel, C.J.; Chauhan, R.S.; Kalyankar, G.G.; Vyas, R.H.; Shah, S.A. Development and validation of HPTLC method for simultaneous estimation of Olmesartanmedoxomil and Cilnidipine in their combined pharmaceutical dosage forms. J Pharm ApplSci, 2015, 2(2), 21.
[92]
Sonia, K.; Lakshmi, K. HPTLC method development and validation: An overview. J Pharm Sci Res., 2017, 9(5), 652.
[95]
Jadhav, M.L.; Girase, M.V.; Tidme, S.K. Development and validation of HPTLC method for simultaneous estimation of valsartan and hydrochlorothiazide in tablet dosage form. J Pharm Biosci, 2015, 3(2), 20-25.
[104]
Naazneen, S.; Sridevi, A. Stability-indicating RP-HPLC method for the simultaneous estimation of azilsartanmedoxomil and chlorthalidone in solid dosage forms. Int. J. Pharm. Pharm. Sci., 2014, 6(6), 236-243.
[105]
Singh, S.; Patel, K.; Agrawal, V.K.; Chaturvedi, S. Stability indicating hptlc method for simultaneous determination of Valsartan and Hydrochlorothiazide In tablets. Int. J. Pharm. Pharm. Sci., 2012, 4(Suppl. 4), 468-471.